Posted by Michael Wonder on 02 Dec 2016
NICE recommends new lung cancer drug pembrolizumab
2 December 2016 - Hundreds of people with advanced lung cancer will now have access to new drug pembrolizumab, also known as Keytruda, after NICE recommends it for routine NHS use.
Pembrolizumab works by targeting a specific protein on the surface of cells which is involved in the body’s immune response to cancer.
In draft guidance NICE has said that adults with advanced lung cancer, that test positive for this protein, should have access to pembrolizumab.
